USP35 and ovarian cancer: Literature reports have also confirmed that in ovarian cancer, USP35 can directly de-ubiquitinate and inactivate STING, thereby enhancing the chemoresistance of ovarian cancer cells to chemotherapy drugs and promoting tumor development [16].